Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944517 | 0.86 | — | — | |
| SCHEMBL21722574 | 0.82 | EPAS1 (0.36) | EPAS1MBTD1L3MBTL3DRD2HRH4 | |
| SCHEMBL5939379 | 0.81 | EPAS1 (0.38) | EPAS1MBTD1L3MBTL3HRH4 | |
| SCHEMBL5939367 | 0.81 | EPAS1 (0.38) | EPAS1MBTD1L3MBTL3HRH4 | |
| SCHEMBL5939649 | 0.81 | EPAS1 (0.38) | EPAS1MBTD1L3MBTL3HRH4 | |
| SCHEMBL5939656 | 0.81 | EPAS1 (0.38) | EPAS1MBTD1L3MBTL3HRH4 | |
| SCHEMBL90804 | 0.72 | MBTD1 (0.44) | EPAS1MBTD1L3MBTL3 | |
| SCHEMBL22915706 | 0.72 | — | — | |
| SCHEMBL13382602 | 0.72 | — | — | |
| SCHEMBL14621027 | 0.72 | MBTD1 (0.44) | EPAS1MBTD1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 519 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150146-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES | NOVARTIS AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| US-12024595-B2 | Polymer composition | BASF SE (DE) | 2024-07-02 | — | — | US | disclosed |
| US-20240182473-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-06 | — | — | US | disclosed |
| EP-4365182-A1 | GEMCITABINE ANTICANCER DERIVATIVE AND ANTICANCER PHARMACEUTICAL USE | Ascentawits Pharmaceuticals, Ltd. (CN) | 2024-05-08 | — | — | EP | disclosed |
| US-20240140970-A1 | A DEUTERATED COMPOUND, AND PREPARATION METHOD AND USE THEREOF | ASCENTAWITS PHARMACEUTICALS LTD (CN) | 2024-05-02 | — | — | US | disclosed |
| CN-117941786-A | Functional beverage and preparation method thereof | 武汉市中心医院 | 2024-04-30 | — | — | CN | disclosed |
| CN-117956998-A | Cancer patients treated for KRAS mutations | 深圳艾欣达伟医药科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117918483-A | Red rice fermented black rice flour and preparation method and application thereof | 武汉市中心医院 | 2024-04-26 | — | — | CN | disclosed |
| EP-4342473-A2 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-02-15 | — | — | US | disclosed |
| EP-1853585-A1 | 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS | Novo Nordisk A/S (DK) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007125105-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125103-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007110364-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007107550-A1 | ADAMANTANE DERIVATIVES FOR THE TREATMENT OF THE METABOLIC SYNDROME | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007101864-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007071766-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007003581-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006087309-A1 | 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS | NOVO NORDISK A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051972-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | EPAS1 3364/4885MBTD1 4279/4885L3MBTL3 2557/4885 |
| US-20240182473-A1 | COMPOUNDS USEFUL IN HIV THERAPY | CD4, CCR5, G6PD | EPAS1 3064/4885MBTD1 4373/4885L3MBTL3 3109/4885 |
| US-20240140970-A1 | A DEUTERATED COMPOUND, AND PREPARATION METHOD AND USE THEREOF | DMPK, DEK, DOHH | EPAS1 2238/4885MBTD1 662/4885L3MBTL3 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.